Key Highlights:

  • Preliminary third quarter revenue is expected at approximately USD 209 million.
  • Next generation sequencing revenue growth is expected at approximately 28% year over year.
  • The company is reiterating its full year total revenue and adjusted EBITDA guidance.
  • Management expects an increase to full year total revenue guidance resulting from third quarter performance.

NeoGenomics, Inc. (NASDAQ:NEO) is scheduled to report third quarter results on Wednesday, Oct. 28, after the market close. Consensus estimates call for adjusted earnings per share of USD 0.06 on revenue of USD 206.70 million, against a market capitalization of USD 2.14 billion.

Ahead of its full results, the company disclosed preliminary third quarter total revenue of approximately USD 209 million, including year over year next generation sequencing revenue growth of approximately 28%, while reiterating its full year total revenue and adjusted EBITDA guidance.

Leadership Transition

Separately, the company announced a planned executive succession under which the current President and Chief Operating Officer is set to become Chief Executive Officer effective January 4, 2027, with the current Chief Executive Officer becoming Executive Chairman at that time.

Figures to Follow in the Release

Investors can watch for final third quarter revenue against the preliminary estimate of approximately USD 209 million and for the extent of any increase to full year guidance.